ELMWOOD PARK, N.J.,
Oct. 9, 2020 /PRNewswire/
-- BioReference Laboratories, Inc., an OPKO Health company
(NASDAQ :OPK), today announced the beginning of its COVID-19
testing program for New York City
schools throughout the 2020-2021 school year to help ensure a safer
school environment.
Continuing a strategic collaboration with New York City, the Department of Health, New
York City Health and Hospital Corporation (NYC Health + Hospitals), the Test & Trace
Corp, and the Department of Education, BioReference is performing
COVID-19 molecular testing for NYC
schools. In addition, BioReference is collecting specimens from
principals, teachers, administration and students from over 950
schools across NYC.
"This school year for New York
City and other school systems around the world is vastly
different due to the global pandemic, and BioReference is
privileged to aid in keeping NYC
schools safe," said Jon R. Cohen,
M.D., Executive Chairman of BioReference Laboratories.
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics,
hospitals, employers, government units, correctional institutions
and medical groups. BioReference has been working
expeditiously to develop and offer test services that will yield
high quality and accurate results, including a molecular test for
helping with COVID-19 diagnosis and a serology test to help
indicate possible COVID-19 exposure. The company is in network with
the five largest health plans in the United States, operates a network of 11
laboratory locations, and is backed by a medical staff of more
than 120 M.D., Ph.D. and other professional level clinicians
and scientists. With a leading position in the areas of genetics,
women's health, maternal fetal medicine, oncology and urology,
BioReference and its specialty laboratories, GenPath and GeneDx,
are advancing the course of modern medicine. For more information,
visit www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational
biopharmaceutical and diagnostics company that seeks to establish
industry-leading positions in large, rapidly growing markets by
leveraging its discovery, development, and commercialization
expertise and novel and proprietary technologies. For more
information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains
"forward-looking statements," as that term is defined under the
Private Securities Litigation Reform Act of 1995 (PSLRA), which
statements may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should,"
"intends," "estimates," and other words of similar meaning,
including statements regarding the role COVID-19 testing will play
in supporting a safer classroom environment, the accuracy and
availability of the test and the role and value of the information
provided and its impact on decisions relative to the safety of
educators, students and their families, as well as other
non-historical statements about our expectations, beliefs or
intentions regarding our business, technologies and products,
financial condition, strategies or prospects. Many factors could
cause our actual activities or results to differ materially from
the activities and results anticipated in forward-looking
statements. These factors include those described in the OPKO
Health, Inc. Annual Reports on Form 10-K filed and to be filed with
the Securities and Exchange Commission and in its other filings
with the Securities and Exchange Commission. In addition,
forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. The forward-looking statements contained in this press
release speak only as of the date the statements were made, and we
do not undertake any obligation to update forward-looking
statements. We intend that all forward-looking statements be
subject to the safe-harbor provisions of the PSLRA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/opko-healths-bioreference-laboratories-launches-covid-19-testing-program-for-new-york-city-schools-301149155.html
SOURCE BioReference Laboratories, Inc